10-Q: Xtant Medical Reports Strong Q3, Strategic Asset Sale Progress

Xtant Medical Holdings, Inc. reported a significant turnaround in net income and gross profit for the nine months ended September 30, 2025, driven by licensing revenue and orthobiologics sales, while progressing with a strategic asset divestiture.

Summary

• Total revenue for the nine months ended September 30, 2025, increased by 18% to $101.6 million, up from $85.8 million in the prior year.
• Net income for the nine months ended September 30, 2025, was $4.9 million, a substantial improvement from a net loss of $13.3 million in the same period of 2024.
• Gross profit margin improved to 65.5% for the nine months ended September 30, 2025, compared to 60.9% in the prior year, primarily due to sales mix and greater scale.
• The company is proceeding with the sale of its Coflex/CoFix assets and international hardware business to Companion Spine, LLC for a total of $19.2 million ($17.5 million for Coflex/CoFix and $1.7 million for Paradigm).
• As of November 3, 2025, $7.5 million in non-refundable cash deposits have been received from Companion Spine, LLC related to the asset sale.
• Net cash provided by operating activities for the first nine months of 2025 was $7.2 million, a significant shift from $12.6 million used in the prior year period.
• Long-term debt under the term loan facility was reduced to $17.0 million as of September 30, 2025, from $22.0 million at December 31, 2024, with further reduction on November 3, 2025.
• Nantahala Capital Management, LLC acquired 49.1% of the company's outstanding common stock in April 2025, becoming a significant shareholder.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with significant improvements in revenue, net income, and cash flow from operations. The strategic asset sale provides liquidity and debt reduction. However, substantial risks remain regarding the completion of the asset sale, the impact of future CMS reimbursement changes, and the potential need for additional capital, which temper the overall positive sentiment.

Positives

• Achieved net income of $4.9 million for the nine months ended September 30, 2025, a significant improvement from a $13.3 million net loss in the prior year.
• Total revenue increased by 18% to $101.6 million for the nine months ended September 30, 2025, driven by $14.1 million in new licensing revenue and increased orthobiologics sales.
• Gross profit margin expanded to 65.5% for the nine months ended September 30, 2025, up from 60.9% in the comparable prior year period, primarily due to favorable sales mix and greater scale.
• Operating expenses decreased by 6.6% to $58.3 million for the nine months ended September 30, 2025, contributing to improved operating income.
• Generated $7.2 million in net cash from operating activities for the first nine months of 2025, reversing a $12.6 million cash usage in the prior year.
• The pending asset sale to Companion Spine, LLC has provided $7.5 million in non-refundable cash deposits, improving liquidity and reducing term loan debt.
• Successfully launched new products including CollagenX, OsteoFactor ProTM, and Trivium, expanding the product portfolio.

Negatives

• The pending sale of Coflex/CoFix assets and international hardware business, if completed, will significantly reduce future revenues.
• Decreased hardware revenue partially offset the overall revenue growth in the current year periods.
• Increased charges for excess and obsolete inventory negatively impacted gross profit by 300 basis points for the three-month comparison and 180 basis points for the nine-month comparison.
• Legal fees increased by $0.5 million for the nine months ended September 30, 2025, primarily associated with the pending transactions.

Risks

• The pending sale of Coflex/CoFix assets and international hardware business may not be completed within the anticipated timeframe or at all, particularly if the buyer fails to obtain financing.
• Diversion of management's attention to complete the transactions could negatively impact existing core business operations.
• Potential loss of key employees, suppliers, customers, distributors, and independent sales agents due to the public announcement and/or completion of the transactions.
• Adverse impact on business, financial condition, and operating results if the transactions are not completed or do not achieve anticipated financial benefits.
• Risk that Companion Spine, LLC may fail to pay the $8.2 million unsecured promissory note due December 31, 2025, if the Coflex/CoFix transaction closes.
• Nantahala Capital Management, LLC's 49.1% ownership could exert substantial influence over corporate decisions, potentially misaligning with other stockholders' interests.
• Future sales of common stock by Nantahala or other investors, or the perception of such sales, could adversely affect the market price of common stock, especially given low trading volume and public float.
• Risk of delisting from the NYSE American Exchange if the common stock trading price decreases to abnormally low levels.
• The biologics business is highly dependent on the availability of human donors and placentas, which could be disrupted by regulatory changes (e.g., FDA draft guidance on sepsis and Mtb) or public opinion.
• CMS policy changes, including proposed fixed reimbursement rates for skin substitutes ($125.38 per square centimeter) effective January 1, 2026, could adversely affect future license revenue and product sales for SimpliMax and SimpliGraft.
• Exposure to global economic slowdown, recession, tariffs, inflation, rising interest rates, and supply chain disruptions, which could result in delayed product launches, lost revenue, higher costs, and decreased profit margins.
• Dependence on and ability to retain and recruit independent sales agents and distributors, particularly key agents responsible for a significant portion of revenue.
• Ability to innovate, develop, introduce, market, and license new products and technologies, and the success of such new products.
• Risks associated with international operations, including foreign currency exchange rate fluctuations, compliance with foreign regulations, and geopolitical tensions.
• Manufacturing challenges related to biologics products and the ability to recover from prior stem cell shortages and win back customers.
• Labor and staffing shortages at hospitals and other medical facilities could reduce elective procedures and product usage, impacting revenues.

Future Outlook

The company anticipates that its current cash, operating cash flows, and available credit facilities will be sufficient to meet cash requirements through at least November 2026. However, it may seek additional capital prior to this time if market conditions are favorable or if needed. The completion of the Coflex/CoFix and international hardware business transactions is expected in the fourth quarter of 2025, but no assurance can be provided regarding the timing or occurrence of these closings. CMS is expected to publish final rules for skin substitute reimbursement in November 2025, with implementation scheduled for January 1, 2026, which could significantly impact future license revenue.

Management Comments

• "We believe that our $10.6 million of cash and cash equivalents as of September 30, 2025, together with our anticipated operating cash flows and amounts available under the Facilities, will be sufficient to meet our anticipated cash requirements through at least November 2026."

Industry Context

The medical technology industry, particularly orthobiologics and spinal implants, is subject to evolving regulatory landscapes and reimbursement policies. The proposed CMS changes for skin substitute reimbursement, setting a fixed price of $125.38 per square centimeter, represent a significant industry trend that could impact companies reliant on these products. The company's focus on new product introductions (CollagenX, OsteoFactor ProTM, Trivium) aligns with the industry's continuous innovation cycle, while its strategic divestiture of non-core assets reflects a broader trend of companies streamlining portfolios to focus on high-growth areas.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Corporate Governance

Legal Proceedings

• The company is subject to potential liabilities under government regulations and various claims and legal actions arising in the ordinary course of business, including commercial, product liability, intellectual property, and employment matters. An estimated loss contingency is accrued if probable and reasonably estimable.

Related Party Transactions

• In April 2025, funds affiliated with Nantahala Capital Management, LLC, an existing stockholder, purchased 57.0 million shares of common stock from OrbiMed Advisors LLC, resulting in Nantahala holding 49.1% of outstanding common stock.
• A family member of Board member Stavros Vizirgianakis also participated in the private secondary resale transaction, purchasing shares from OrbiMed.
• The company entered into a registration rights agreement with the purchasers to facilitate the resale of shares, agreeing to file a shelf resale registration statement and indemnify selling stockholders for certain liabilities.

Stakeholder Impact

• **Shareholders:** Significant improvement in net income and cash flow could be positive. However, potential dilution from future capital raises, the impact of the asset sale on future revenues, and the concentration of ownership by Nantahala (49.1%) could affect voting power and market price.
• **Customers:** The pending sale of Coflex/CoFix and international hardware business may lead to changes in product availability or service for those specific lines. New product introductions (CollagenX, OsteoFactor ProTM, Trivium) offer expanded solutions.
• **Employees:** Potential loss of key employees is a risk associated with the pending asset sale. The company also faces challenges in attracting and retaining qualified personnel in a tight labor market.
• **Creditors (MidCap):** The company is in compliance with all debt covenants, and prepayments from asset sale deposits have reduced the term loan, improving the credit profile related to MidCap.

Next Steps

• Complete the pending sale of Coflex/CoFix assets and international hardware business to Companion Spine, LLC (expected Q4 2025).
• Companion Spine, LLC to obtain financing for the asset purchase.
• CMS to publish final rules for skin substitute reimbursement (anticipated November 2025, effective January 1, 2026).
• The $8.2 million unsecured promissory note from Companion Spine, LLC is due to mature on December 31, 2025.
• Evaluate and potentially pursue additional financing through equity, debt, or strategic transactions prior to November 2026.

Key Dates

Recommendation

The company has demonstrated a strong financial turnaround with significant improvements in revenue, net income, and operating cash flow, which are positive indicators. The strategic divestiture of non-core assets provides immediate liquidity and reduces debt. However, the future impact of this asset sale on revenue, the ongoing uncertainty surrounding critical CMS reimbursement policy changes for key products, and the substantial concentration of ownership by Nantahala Capital Management, LLC introduce considerable risks. The explicit statement about potentially needing additional capital prior to November 2026 also suggests future dilution or increased debt. Given the mix of strong recent performance and significant forward-looking uncertainties, a 'hold' recommendation is appropriate for a seasoned investor to monitor the execution of the asset sale, the resolution of CMS policies, and the company's capital structure.

Keywords

Orthobiologics, Spinal Implants, Medical Technology, SEC Filing, 10-Q, Financial Results, Asset Sale, Licensing Revenue, Net Income, Gross Margin, Cash Flow, Debt Reduction, CMS Reimbursement, Nantahala Capital, Biologics Supply Chain, Product Development